Error Reduction and Prevention in Surgical Pathology. Raouf E. Nakhleh, MD Professor of Pathology Mayo Clinic Florida



Similar documents
Factors Affecting Patient Safety and Error Reduction in Surgical Pathology

Specimen Labeling Errors in Surgical Pathology An 18-Month Experience

CAP Laboratory Improvement Programs. Mislabeling of Cases, Specimens, Blocks, and Slides. A College of American Pathologists Study of 136 Institutions

Identifying and Avoiding Errors in Surgical Pathology

Customer Satisfaction in Anatomic Pathology. A College of American Pathologists Q-Probes Study of 3065 Physician Surveys From 94 Laboratories

PATIENT SAFETY DIAGNOSTIC ERROR SURGICAL PATHOLOGY

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Patient Safety and the Laboratory

Patient Misidentification in Laboratory Medicine. A Qualitative Analysis of 227 Root Cause Analysis Reports in the Veterans Health Administration

Surgical specimen identification errors: A new measure of quality in surgical care

Early Prostate Cancer: Questions and Answers. Key Points

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

2009 LAP Audioconference Series. How to Prepare and Comply with Your Quality Management Plan

Science Highlights. To PSA or not to PSA: That is the Question.

Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports

September 5, Linda Stewart Vice President, National Lab Program UnitedHealthcare Group P.O. Box 1459 Minneapolis, MN

Leica CEREBRO Sample Tracking. Patient Safety. Enhanced Productivity. Complete Flexibility.

The Diagnosis of Cancer in the Pathology Laboratory

Liron Pantanowitz, MD

YOUR LUNG CANCER PATHOLOGY REPORT

Targeted Therapy What the Surgeon Needs to Know

JOINT COMMISSION INTERNATIONAL ACCREDITATION STANDARDS FOR. 2nd Edition

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Histology Asset Tracking March 3, 2013

Relational Coupling by 2-D Barcodes A Novel Approach to Positive Patient and Specimen Identification in Tissue and Cytology Specimens

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach

Medical Laboratory Technology Program. Student Learning Outcomes & Course Descriptions with Learning Objectives

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Us TOO University Presents: Understanding Diagnostic Testing

General Information. Our Background Automated Phone Services Holiday Coverage Licenses & Accreditations

Below are some of the ways pathologists contribute to the six domains (listed in the order they appear on page 2 of the Strategy):

Standards for Laboratory Accreditation

Thymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.

Lisa Yerian, MD May 12, 2011

LAP Audioconference How to Prepare and Comply with Your Quality Management Plan* February 18, 2009

Oklahoma Facts CPT. Definitions. Mohs Micrographic Surgery. What Does That Mean? Billing and Coding for Mohs Surgery

OBJECTIVES By the end of this segment, the community participant will be able to:

Diagnosis of Mesothelioma Pitfalls and Practical Information

HER2 Testing in Breast Cancer

Sutter Health Support Services Shared Laboratory Position Description. Incumbent: Laboratory Date: October 23, 2006 Written By: Michele Leonard

Section 7: Program Objectives and Supervision of Residents at USC University Hospital

Brain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.

Frozen Section Diagnosis

Practical Effusion Cytology

Prepublication Requirements

What is a definition of risk?

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? Telephone

Classificazioni citologiche: verso uno schema internazionale unificato?

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid

Errors in Pathology and Laboratory Medicine: Consequences and Prevention

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

1. What is the prostate-specific antigen (PSA) test?

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1

Urinalysis Compliance Tools. POCC Webinar January 19, 2011 Dr. Susan Selgren

Nicole Kounalakis, MD

Going Beyond Laboratory Automation: Do Less Accomplish More. Swedish Covenant Hospital

BRAF in the diagnostic evaluation of thyroid nodules

White Paper Synoptic Reporting and Structured Data Capture

If you are signing for a minor child, you refers to your child throughout the consent document.

Quality Management Tools

The Ontario Cancer Registry moves to the 21 st Century

FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts

Best Practices for Maintaining Quality in Molecular Diagnostics Gyorgy Abel, MD, PhD

Explanation of your PAP smear

Pleural and Pericardial fluids a one year analysis

Managing POCT: Trying to Control Testing in an Out-of-Control Environment. William Clarke, PhD, MBA, DABCC Johns Hopkins School of Medicine 3/24/11

ELECTRONIC MEDICAL RECORDS (EMR)

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer

Adekunle M Adesina, M.D., Ph.D

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Laboratory Quality Metrics

Identifying and Resolving Failure Modalities at the LIS/EHR Interface October 9, Teresa Darcy MD, MMM

Cervical Cancer The Importance of Cervical Screening and Vaccination

Guideline Development The American Society of Clinical Oncology

The Role of the Laboratory in Clinical Trials. Basma Elgamal, M.D. Professor of Clinical Pathology National Cancer Institute, Cairo University

Conflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.

05/01/11-02/28/2013 Lincoln Diagnostics LLC Medical Director, started 06/01/ Josephine Street Staten Island, N Y, 10314

The PSA Test for Prostate Cancer Screening:

Disclosing Medical Errors: 2008 and Beyond. Wendy Levinson, MD Professor of Medicine University of Toronto

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Technology Assisting Cancer Outcomes: Automated Biomarker Abstraction Overcoming Textual Data-Silos

Guide to Understanding Breast Cancer

SUPPLEMENTARY NOTES. Personal General Insurance (4 th Edition) Date Of Issue: 1 October 2014

Lean Strategies Used to Optimize Automation. Why Lean Six Sigma? Laboratory Goals. Decreased TAT. Accurate Results. LEAN Goals.

Development of Automated Testing Solution for Sunquest CoPathPlus 6.0

Materials and Methods

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

EARLY ONLINE RELEASE

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

Table of Contents. Cancer Committee Chairman s Report Accountability and Quality Improvement Measures Cancer Registry Cancer Sites

4/24/2015. Urgent, STAT, Super STAT, ASAP! Achieving timely lab testing for the Emergency Department. Learning Objectives.

2010 Laboratory Accreditation Program Audioconference. Accreditation Requirements for Waived Vs. Non-waived Tests

The Henry Ford Production System Measures of Process Defects and Waste in Surgical Pathology as a Basis for Quality Improvement Initiatives

Immunohistochemical differentiation of metastatic tumours

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH (603)

Transcription:

Error Reduction and Prevention in Surgical Pathology Raouf E. Nakhleh, MD Professor of Pathology Mayo Clinic Florida

Disclosure None 2

Course Objectives At the end of the presentation participants should be able to: Identify where errors occur within the test cycle Implement effective methods to help detect and prevent errors Apply general principles of error reduction to enhance the overall quality of surgical pathology 3

Agenda Source, frequency and significance of errors General principles of error reduction Identification (pre-analytic) errors Diagnostic (analytic) error Post-analytic errors 4

Error Rates Safrin & Bark, 1993 Whitehead, 1985 # of Cases Case Selection 5,397 Consecutiv e 3,000 Consecutiv e Lind, 1995 2,694 Diagnostic Bx Error Rate(%) Sig. Error Rate(%) 0.5 0.26 7.8 0.96 13 1.2 Lind, 1995 480 Random 12 1.7 Renshaw, 2003 11,683 0.0-2.36 0.34-1.19 Raab, 2008 7,444 380 5% Random Focused 2.6 13.2 0.36 3.2

Error Rates Inter-institutional review Error Rate (%) Significant Error Rate (%) Kronz, 1999 N/A 1.4 Abt, 1995 7.8 5.8 Gupta, 2000 1 30 2 5 Malhotra, 1996 11.6 N/A Weir, 2001 6.8 3.7 Tsung, 2004 11.1 5.9 Swapp, 2012 5.4 0.6

Errors in Surgical Pathology Pre-analytic Wrong identification: 27-38% Defective specimens: 4-10% Analytic Diagnostic mis-interpretation: 23-29% Post-analytic Defective report: 29-44% Am J Clin Pathol 2008;130:238-246

The Doctors Company Am J Surg Pathol 2004;28:1092-1095 272 surgical pathology claims (1998-2003) 166 (61%) false negative 73 (27%) false positive 10 (4%) frozen section 22 (8%) operational Analytic 13 mix-ups Pre-analytic 3 floaters Analytic Post-analytic 2 mislabeled biopsy site One transcription error, no omitted before malignant cells

171 Jury Verdict and Settlements Arch Pathol Lab Med. 2007;131:615-618 LexisNexis search Surgical Pathology Cytology 1988-1993 26 9 16 1994-1999 25 20 14 2000-2005 33 19 9 Clinical Pathology Total 84 (49%) 48 (28%) 39 (23%)

Surgical Pathology Cases False negative, 73% False positive, 19% Analytic System errors, 8% Pre-analytic 4 lost or mixed-up specimens 2 floaters lead to false positive 1 no communication of lack of chorionic villi in POC leading to ruptured tube Post-analytic

Risk Pre-analytic Specimen identification Clinical information Analytic Diagnostic accuracy Post-analytic Report completeness Communication of significant results

Specific Factors That Lead to Errors Hand-offs Weak links Complexity Risk of error increases with every step Inconsistency Level of training, performance, procedures, communication, language or taxonomy

Specific Factors That Lead to Errors Human intervention Machines are better at routine tasks Humans are better in unexpected conditions Time constraints Forces compromise Inflexible hierarchical culture

General Error Reduction Methods Standardize all procedures Remove distractions Accessioning, grossing, cutting, microscope, sign-out Make people aware of this potential Automate where possible Specimen handling, analyzers Comprehensive computer systems

General Error Reduction Methods Remove inconsistent tools Handwriting Reduce complexity Automation Lean design Make everyone aware of hand-offs (problem points) Reduce reliance on memory Checklists

General Error Reduction Methods Enhance communication Electronic medical record Computer physician order entry (CPOE) Adequate and appropriate staffing Batch work Redundancy Suitability Adequate and appropriate facilities Space, lighting Reduce the stress level

General Principles of Error Reduction Sustained error reduction generally comes with a comprehensive persistent effort Unlikely to succeed with one intervention Continuously examine and redesign systems Build-in prevention and detection systems through QA and QC measures

General Principles of Error Reduction Continuously monitor and analyze QA and QC data Intervene at the earliest sign of variations Share quality assurance data Communicate to all workers that their work matters to patients

Pre-analytic Errors Specimen identification Specimen collection Specimen labeling Specimen fixation Specimen transport Accessioning

Specimen Identification Reasons for ID errors Dependent of numerous individuals and locations outside the control of the laboratory Inconsistent training Inconsistent application of labeling standards

Specimen Identification CAP study of 1 million surgical specimens in 417 Laboratories 6% deficiencies (Median 3.4%) Specimen ID problems 9.6% Information problems 77% Handling problems 3.6% Others 9.7% Arch Pathol Lab Med 1996;120:227

Root Cause Analysis of VA Laboratories Arch Pathol Lab Med 2010;134:244-255 227 Root Cause Analysis Reports ID errors accounted for 182/253 adverse events 132 (73%) pre-analytic, 37 (20%) analytic, 13 (7%) post-analytic Mislabeling associated with batching (35) Manual entry of lab forms (14) Failure of 2 person verification in blood bank (20) 27/37 analytic relabeling of containers-blocksspecimens

Specimen Identification Joint Commission patient safety goal Improve the accuracy of patient identification CAP patient safety goal Improve patient and sample identification Mishaps have led to disastrous examples of wrong surgery or treatment

Specimen Identification PSG provide the muscle to be able to attack this problem Need to adopt specimen identification as an institutional goal (change the culture) QA measure for clinics, OR, etc. Cannot be achieved from within the laboratory

Specimen Identification Sustained awareness campaign Change the culture Extensive education and training with annual refresher sessions Recent report of specimen time-out in the OR Strict adherence to labeling standards and labeling procedures Remote order entry (forcing function) Newer technology may be helpful Recent reports of DNA time out Make everyone in the process aware of pitfalls and the possibility of misidentified specimens

Factors that Improve Performance Limit preprinting of labels (batch printing) Look for ID errors prior to release of results (QC checks) Investigate patient ID when not on file Continuously monitor ID errors Check report vs. requisition Use strict acceptance (rejection) criteria Arch Pathol Lab Med 2006;130:1106-1113

Improvement in Patient Identification 1 year, 0.8% 2 years, 2.7% 3 years, 3.8% 4 years, 4.1% 5 years, 5.6% 6 years, 6.2% Arch Pathol Lab Med 2003;126:809-815

Specimen ID Surgical specimen identification error: A new measure of quality in surgical care. Surgery 2007;141:450-5 Dept of Surgery, John Hopkins 21,351 surgical specimens 91 surgical specimen (4.3/1000) ID errors 18 not labeled 16 empty containers 16 laterality incorrect 14 incorrect tissue site 11 incorrect patient 9 no patient name 7 no tissue site 0.512% outpatient clinic, 0.346% operating rooms

Gross Room and Histology Lab Significant opportunity for error 2009 Q-Probes study in 136 labs 1.1/1000 mislabeled cases 1.0/1000 mislabeled specimens 1.7/1000 mislabeled blocks 1.1/1000 mislabeled slides

Gross Room and Histology Lab Error frequency Before and at accessioning 33.3 % Block labeling and dissection 31.9 % Tissue cutting and mounting 30.4% Errors detected at the one or two steps immediately after the error Include periodic error checks throughout the system

Gross Room and Histology Lab Solutions Lean redesign Am J Clin Pathol 2009;131:468-477 Reduce case ID errors 62% Reduce slide ID errors 95% Lean production advantages Eliminates procedural steps (simplification) Aligns and even out workflow (eliminate batch work) Judicial use of technology Barcodes, readers, labelers (consistency) Standardization of procedures (consistency)

Error Factors Factors that correlated with error Pathologist Specimen type (breast, gyn >>GI, Skin) Diagnosis (non-dx, atypia >>neg) Sub-specialization # of pathologist on report Factors not correlated with error Workload Years of experience Use of special stains Am J Clin Pathol 2007;127:144-152

Accurate Interpretive Diagnoses Knowledge, Experience and Training Standardization of Terminology and Procedures Clinical History and Clinical Correlation Ancillary Studies Case Reviews

Knowledge, Experience and Training Initial qualification Medical school, residency, boards JC Focused professional practice evaluation (FPPE) Ongoing education and ongoing competence assessment ABP four part MOC process JC Ongoing professional practice evaluation (OPPE)

Standardization of Terminology and Procedures Diagnostic terminology Cancer diagnosis/checklists Non-cancer diagnosis Banff rejection grading Hepatitis grade and stage Etc. Laboratory and sign-out procedures

Standardized Diagnostic Criteria Breast borderline lesions Rosai Am J Surg Pathol 1991;15:209-21 17 proliferative lesions 5 pathologists with interest in breast disease Each used his/her criteria No agreement on any case by all 5 pathologists 33% diagnoses spanned hyperplasia to CIS Some pathologists consistently more benign or more malignant High level of variability

Standardized Diagnostic Criteria Schnitt Am J Surg Pathol 1992;16:1133-43 24 proliferative lesions Six expert breast pathologists Used the same diagnostic criteria (Page) Complete agreement in 58% of cases Agreement of 5 or more in 71% Agreement of 4 or more in 92% No pathologists was more benign or malignant than others

Standardized Diagnostic Criteria Use of standardized checklists Increases report completeness Everyone uses the same language Facilitates establishment and comparison of treatment protocols Forces pathologists to update their knowledge Motivation for ongoing educations CME Checklist what does this mean, how do I evaluate this?

Standardization of Procedures and Terminology Sign out procedures Use of standardized terminology Use of checklist Selected case reviews before sign-out Laboratory procedures Fixation time Gross room dissection and taking sections. Consistent uniform processing of tissue (fixation, cutting, staining) Automation (usually leads to more uniform procedures)

Clinical History and Clinical Correlation Understanding the clinical question In part why sub-specialists do better at addressing specific situations. Affects report completeness Affects diagnostic accuracy R/O tumor Medical disease

Clinical History Clinical information in surgical pathology 771,475 case from 341 institutions 2.4% of cases have no history 5594 (0.73%) required additional information 31% resulted in a delay in diagnosis 6.1% of cases new information lead to substantial change in diagnosis Arch Pathol Lab Med 1999;123:615-619

Clinical History Study of amended reports 10% additional clinical history 20% clinician identifies clinicopathologic discrepancy Arch Pathol Lab Med. 1998;122:303-309 Malpractice Claims 20% failure to obtain all relevant information Am J Surg Pathol 1993;17:75-80

Clinical History Solutions Electronic medical record Multidisciplinary teams Tumor board or other multidisciplinary conference Sub-specialization

Ancillary Studies Mostly a blessing for pathologists Must work hard to maintain reliability of ancillary studies Complex systems requiring stringent quality control and quality assurance

Metastatic Melanoma? Melan A HMB-45

Ancillary Studies Help determine cell lineage and diagnosis Prostate specific antigen HMB45, Melan A TTF-1 Thyroglobulin CD 117 Help determine therapy ER, PR, HER2 BRAF, KRAS, ALK, EGFR, CD117, CD20

Redundancy (Review of Cases) Principle method used to prevent or detect cognitive errors Most AP labs have limited # of specimens for double read Breast, thyroid, pigmented skin lesions, Barrett s dysplasia, Brain tumors Taught early in training (instinctive) One method to keep up to date Problematic for small groups

Consultations 0.5% of all cases (median.7%, 0-2%) Arch Pathol lab med 2002;126:405-412 Less in larger groups Presence of experts on staff ASCP guidelines Am J Clin Pathol 2000;114:329-335 Problem prone case Defined by the individual, group, clinician, patient or literature

Frequency of Routine Second Opinion Benign diagnosis Breast 6% Prostate 18% Nevi 8% Malignant diagnosis Breast CA on needle Bx 42% Prostate CA on needle Bx 43% Melanoma 58% GI CA on biopsy 34% Unpublished data (2001) from PIP program

Routine Review Before Sign-out CAP 2008 Q-Probes study Archives Pathol Lab Med 2010;134:740-743 45 Laboratories, 18,032 cases 6.6% (median 8.2%) had review before signout 78% reviewed by one additional pathologist. 46% for a difficult diagnosis 43% per departmental policy

Routine Review Before Sign-out 45% malignant neoplasm Most common organ systems GI 20%, breast 16%, skin 13%, GYN 10% Labs with review policy Higher review rates (9.6% vs. 6.5%) Reviewed a higher % of malignancies (48% vs. 36%)

Routine Second Opinion 13% of case were seen by >1 pathologist Disagreement rate 4.8% vs. 6.9%, P=.004 Amended report rate 0.0 vs. 0.5% Best selection of case to be reviewed remains unknown Am J Clin Pathol 2006;125:737-739

Routine Second Opinion Comparison of rates of misdiagnoses over two one year periods Without routine second review With routine second review Results 10 misdiagnoses without review out of 7909 cases (1.3%) 5 misdiagnoses with review out of 8469 cases (0.6%) Pathology Case Review 2005;10:63-67

Routine Second Opinion Study of amended reports 1.7 million cases in 359 labs 1.6/1000 amended report reviewed after sign-out 1.2/1000 amended reports reviewed before sign-out Arch Pathol Lab Med. 1998;122:303-309

Pre-Sign out Quality Assurance Tool Am J Surg Pathol 2010;34:1319-1323 Randomly selects an adjustable % of case for review by a second pathologist Disagreements similar to retrospective reviews TAT slightly shorter (P=0.07) Amended reports decreased by 30% Amended reports for diagnostic edit decreased 55%

Method of Review (Renshaw and Gould) Tissue with highest amended rates: Breast 4.4%, endocrine 4%, GYN 1.8%, cytology 1.3% Specimen types with highest amended rates: Breast core bx 4.0%, Endometrial curettings 2.1% Diagnoses with highest amended rates: nondx 5%, atypical/suspicious 2.2% Am J Clin Pathol 2006;126:736-7.39

Method of Review (Renshaw and Gould) Reviewing nondiagnostic and atypical /suspicious review 4% of cases and detect 14% of amended reports Reviewing all breast, GYN, non-gyn cytology and endocrine material review 26.9% of cases and detected 88% of amended reports.

Method of Review (Raab et al) Targeted 5% random review vs. focused review 5% random review 195/7444 cases (2.6%) Focused review 50/380 cases (13.2%) Thyroid gland (pilot), GI, bone and soft tissue, GU P<.001 Major errors: Random 27(0.36%) vs. Focused 12 (3.2%) Am J Clin Pathol 2008;130:905-912

Post-Analytic Risk Complete reports Effective and timely communication of important results

Post-analytic Complete reporting Evidence based medicine: oncology Commission on Cancer of the American College of Surgeons Cancer Program Standards 2004 90% of cancer reports must have required elements based on the CAP s publication Reporting on Cancer Specimens Summary checklists

Post-analytic Branston et al. European J Cancer 38;764:2002 Randomized controlled trial of computer form-based reports 16 hospitals in Wales 1044 study, 998 control 28.4% increase in report completeness Acceptable by pathologist Preferred by clinicians

Critical Value Policies Based on regulatory mandates all institutions have critical value policies Policies apply to clinical pathology, radiology and other areas where testing is done (cardiology, respiratory therapy, etc) Policies typically mandate that result is reported within a specified timeframe (usually 30 or 60 min) Clinical Labs report >95% within 30 min 66

Effective Communication of Important Results Regulatory mandates CLIA 88 immediately alert an imminent life- threatening condition, or panic or alert values Joint Commission develop written procedures for managing the critical results, define CR, by whom and to whom, acceptable time LAP There is a policy regarding the communication, and documentation thereof, of significant and unexpected surgical pathology findings

Surgical Pathology and Cytology Tissue processing takes hours and up to a day to complete Why 30-60 min to report??? Critical most diagnoses are important for treatment but not imminently life threatening Poor agreement among pathologists and clinicians Most reported cases of patient harm related to communication problems are due to lack of communication or missed communication not delay 68

Pereira et al AJCP 2008;130:731 Do you believe that there are critical values in: Surgical Pathology, 44/73 yes, 24 blank Cytology, 31/57 yes, 22 blank Surgical Pathology Call ASAP Bacteria in heart or BM 91% Organism in immune compromised patient 85% Cytology Call ASAP Bacteria or fungi in CSF 81% and 88% 2010 College of American Pathologists. All rights reserved. 69

Effective Communication of Important Results Arch Pathol Lab Med 2009;133:1375 1130 Laboratories surveyed 75% had AP Critical Diagnosis policy 52% of those with policy listed specific diagnoses Specific conditions included in the policy All malignancies 48.3% Life threatening infection 44.6% 70

Effective Communication of Important Results Arch Pathol Lab Med 2012;136:148-154 Urgent diagnoses Imminently life threatening Very short list Reported quickly e.g. New infection in an immune compromised patient Significant unexpected diagnoses Not imminently life threatening Unusual or unexpected Difficult to anticipate Needs communication & documentation e. g. carcinoma in biopsy taken for medical disease

Summary Source, frequency and significance of errors General principles of error reduction Identification errors (pre-analytic) Reasons for diagnostic (analytic) error Clinical history and clinical correlation Prospective and retrospective case reviews Post-analytic errors Report completeness Communication beyond the report 72

Thank You! Questions?